Literature DB >> 22973357

Comparison between the efficacy of Q-Switched 1064-nm Nd: YAG laser and Fraxel CO(2) laser on improvement of atrophic facial acne scars: A letter to editor.

Neda Adibi1.   

Abstract

Entities:  

Year:  2011        PMID: 22973357      PMCID: PMC3430073     

Source DB:  PubMed          Journal:  J Res Med Sci        ISSN: 1735-1995            Impact factor:   1.852


× No keyword cloud information.
I read with interest the article of Dr Asilian and coauthors entitled “Comparison between the efficacy of Q-Switched 1064-nm Nd:YAG laser and Fraxel CO2 laser on improvement of atrophic facial acne scars” in this journal. In this article the authors concluded a better efficacy for fractional CO2laser in comparison with 1064-nm Q-switched NdYag laser.1 Treatment of the atrophic acne scars is a real challenge in cosmetic dermatology. However, the fractional lasers are ablative laser techniques and are the optional choices with higher efficacy than non-ablatives approaches liket NdYag. There is a general consensus about the higher efficacy of ablative methods in comparison with non-ablative ones in the treatment of atrophic acne scars because of their underlying mechanism making them the treatment of choice in the literature.2 It might be suggested to select the same laser types for research purposes with respect to their mechanism (from both ablative and non-ablative ones) instead of these two ones which belongs to different laser categories with previously well known different types of action. I should also note that it is the laser parameters that show its efficacy, consisted of the wave length, fluency, spot size pulse type and the number of treatment sessions. Lasers that were previously used in other studies for treating acne scars were almost always from 1320-nm short pulsed Nd:YAGs, so the selection of 1064-nm Q-switched one should have had a more detailed explanation by the authors.34 There are very limited researches in the literature about using 1064-nm laser in the treatment of acne scars. Lipper and Perez used this wave length but they used short pulsed type lasers instead of Q-switched and their selected fluency was 14j/cm2 and they treated patients for eight laser sessions.5 The 2.5 j/cm2 fluency and four numbers of sessions which were selected in the Dr. Asilian's work are low numbers with respect to Lipper's study. Therefore, it may have had a negative influence on their final results in comparison with Lipper's findings. I should appreciate the Dr. Asilian and his colleagues for their definite methodology especially in the field of selecting the patient skin types to reduce the side effects of laser and also the very well organized follow up. In addition, the use of blinded dermatologists for evaluating the final results was another excellent way to reduce the research bias.
  5 in total

1.  Nonablative acne scar reduction after a series of treatments with a short-pulsed 1,064-nm neodymium:YAG laser.

Authors:  Graeme M Lipper; Maritza Perez
Journal:  Dermatol Surg       Date:  2006-08       Impact factor: 3.398

2.  Efficacy and safety of a carbon-dioxide ablative fractional resurfacing device for treatment of atrophic acne scars in Asians.

Authors:  Woraphong Manuskiatti; Daranporn Triwongwaranat; Supenya Varothai; Sasima Eimpunth; Rungsima Wanitphakdeedecha
Journal:  J Am Acad Dermatol       Date:  2010-08       Impact factor: 11.527

3.  Atrophic and a mixed pattern of acne scars improved with a 1320-nm Nd:YAG laser.

Authors:  Arlene S Rogachefsky; Mussarat Hussain; David J Goldberg
Journal:  Dermatol Surg       Date:  2003-09       Impact factor: 3.398

4.  A preliminary study of utilization of the 1320-nm Nd:YAG laser for the treatment of acne scarring.

Authors:  Neil S Sadick; Amy K Schecter
Journal:  Dermatol Surg       Date:  2004-07       Impact factor: 3.398

5.  Comparison of Q-Switched 1064-nm Nd: YAG laser and fractional CO2 laser efficacies on improvement of atrophic facial acne scar.

Authors:  Ali Asilian; Elias Salimi; Gita Faghihi; Farideh Dehghani; Nabet Tajmirriahi; Sayed Mohsen Hosseini
Journal:  J Res Med Sci       Date:  2011-09       Impact factor: 1.852

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.